0,05. Доказательная медицина от магии до поисков бессмертия - Петр Талантов

Lindsay G. B., Merrill R. M., Hedin R. J. The contribution of public health and improved social conditions to increased life expectancy: an analysis of public awareness // Journal of Community Medicine and Health Education. 2014. Vol. 4. P. 311.

Ten great public health Achievements – United States, 1900–1999 // MMWR. 1999. April 2. Vol. 48. № 12. P. 241–243.

Bunker J. P., Frazier H. S., Mosteller F. Improving health: measuring effects of medical care // The Milbank quarterly. 1994. Vol. 72. № 2. P. 225–258.

McKinley J. B., McKinley S. M. The questionable contribution of medical measures to the decline of mortality in the United States in the twentieth century // The Milbank Memorial Fund quarterly. Health and society. 1977. Summer. Vol. 55. № 3. P. 405–428.

Bunker J. P. The role of medical care in contributing to health improvements within societies // International Journal of Epidemiology. 2001. December 1. Vol. 30. № 6. P. 1260–1263.

Murray C. J. L. Why is Japanese life expectancy so high? // Lancet. 2011. September 24. Vol. 378. № 9797. P. 1124–1125.

Shiro Horiuchi Major causes of the rapid longevity extension in postwar Japan // The Japanese Journal of Population. 2011. March. Vol. 9. № 1. P. 162–171.

Crimmins E. M., Preston S. H., Cohen B. (eds) Explaining divergent levels of longevity in high-income countries. Washington (DC): National Academies Press (US), 2011.

Marmot M. G. Status syndrome: A challenge to medicine // JAMA. 2006. Vol. 295. № 11. P. 1304–1307.

Marmot M. The status syndrome: How social standing affects our health and longevity. New York, NY: Henry Holt and Company, 2004.

Marmot M. G., Rose G., Shipley M., Hamilton P. J. S. Employment grade and coronary heart disease in British civil servants // Journal of epidemiology and community health. 1978. Vol. 32. № 4. P. 244–249.

Adler N., Ostrove J. Socioeconomic status and health: what we know and what we don’t /Adler N., Marmot M., McEwen B., Stewart J. (eds.) Socioeconomic status and health in industrial nations. New York, NY: New York Academy of Sciences, 1999. P. 3–15.

Mackenbach J. P., Bos V., Andersen O. et al. Widening socioeconomic inequalities in mortality in six Western European countries // International Journal of Epidemiology. 2003. Vol. 32. P. 830–837.

McDonough P., Duncan G. J., Williams D., House J. S. Income dynamics and adult mortality in the United States, 1972 through 1989 // The American Journal of Public Health. 1997. Vol. 87. № 9. P. 1476–1483.

Britton A., Shipley M., Marmot M., Hemingway H. Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study // BMJ. 2004. Vol. 329. № 7461. P. 318–323.

Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva, World Health Organization, 2008.

Franco Á., Álvarez-Dardet C., Ruiz M. T. Effect of democracy on health: ecological study // BMJ. 2004. December 18. Vol. 329. № 7480. P. 1421–1423.

Johanson R., Newburn M., Macfarlane A. Has the medicalisation of childbirth gone too far? // BMJ. 2002. Vol. 324. № 7342. P. 892–895.

Kaunitz A. M., Spence C., Danielson T. S., Rochat R. W., Grimes D. A. Perinatal and maternal mortality in a religious group avoiding obstetric care // American Journal of Obstetrics & Gynecology. 1984. December 1. Vol. 150. № 7. P. 826–831.

Stamatakis E., Weiler R., Ioannidis J. P. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review // European journal of clinical investigation. 2013. Vol. 43. № 5. P. 469–475.

Moynihan R., Doran E., Henry D. Disease mongering is now part of the global health debate // PLoS Medicine. 2008. Vol. 5. № 5, e106.

Simons J. The $ 10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history. Here’s how Pfizer did it // Fortune. 2003. January 20. Vol. 147. № 1. P. 58–62.

Лечение ОРВИ и гриппа в рутинной клинической практике // Фармацевтический вестник. 2017. 28 июля.

Мизерницкий Ю. Л. Применение инновационного отечественного индуктора интерферона для профилактики и лечения острых респираторных вирусных инфекций у детей // Медицинский совет. 2016. № 1. С. 50–53.

Харламова Ф. С., Кладова О. В., Сергеева Э. М. и др. Клиническая эффективность препарата Кагоцел® при гриппе и ОРВИ у детей с 2 до 6 лет // Детские инфекции. 2010. № 4. С. 34–41.

Вартанян Р. В., Сергеева Э. М., Чешик С. Г. Оценка терапевтической эффективности препарата Кагоцел® у детей младшего и дошкольного возраста с острыми респираторными вирусными инфекциями // Детские инфекции. 2011. № 1. С. 36–41.

Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE seeding trial: A review of internal documents // Annals of Internal Medicine. 2008. Vol. 149. № 4. P. 251–258.

Krimsky S., Rothenberg L. S., Stott P., Kyle G. Scientific journals and their authors’ financial interests: A pilot study // Psychotherapy and psychosomatics. 1998. July-October. Vol. 67. № 4–5. P. 194–201.

Papanikolaou G. N., Baltogianni M. S., Contopoulos-Ioannidis D. G. et al. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions // BMC medical research methodology. 2001. Vol. P. 3.

Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? // PLoS Medicine. 2007. Vol. 4. № 9, e286.

Mirowski P., Van Horn R. The contract research organization and the commercialization of scientific research // Social studies of science. 2005. August. Vol. 35. № 4. P. 503–548.